Financial Ratios HBM Healthcare Investments AG
Equities
HBMN
CH0012627250
Investment Management & Fund Operators
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 206.00 CHF | +0.24% |
|
-0.96% | +17.05% |
| Nov. 17 | DKSH Reportedly to Weigh Bid for Pharma Distributor Swixx Biopharma | CI |
| Nov. 17 | DKSH Emerges as Contender for Swiss Drug Service Company Swixx BioPharma | MT |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 24.87 | -2.14 | -4.42 | 0.02 | 0.7 | |||||
Return on Total Capital | 24.96 | -2.15 | -4.43 | 0.02 | 0.7 | |||||
Return On Equity % | 42.01 | -3.77 | -7.78 | -0.06 | 1.11 | |||||
Return on Common Equity | 42.01 | -3.77 | -7.78 | -0.06 | 1.11 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | 100 | 100 | 100 | 100 | |||||
SG&A Margin | 1.21 | -1.02 | -0.5 | 53.79 | 7.1 | |||||
EBITA Margin % | 98.69 | 102.08 | 101 | 17.44 | 88.79 | |||||
EBIT Margin % | 98.69 | 102.08 | 101 | 17.44 | 88.79 | |||||
Income From Continuing Operations Margin % | 98.37 | 105.76 | 102.86 | -36.32 | 83.07 | |||||
Net Income Margin % | 98.37 | 105.76 | 102.86 | -36.32 | 83.07 | |||||
Net Avail. For Common Margin % | 98.37 | 105.76 | 102.86 | -36.32 | 83.07 | |||||
Normalized Net Income Margin | 61.48 | 66.1 | 64.29 | -22.7 | 51.92 | |||||
Levered Free Cash Flow Margin | 62.37 | 77.73 | 64.2 | 12.12 | 51 | |||||
Unlevered Free Cash Flow Margin | 62.57 | 75.43 | 63.03 | 47.69 | 54.71 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.4 | -0.03 | -0.07 | 0 | 0.01 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.1 | 2.64 | 0.11 | 3.1 | 0.81 | |||||
Quick Ratio | 0.1 | 2.64 | 0.11 | 3.1 | 0.81 | |||||
Operating Cash Flow to Current Liabilities | -0.05 | -4.99 | -0.02 | -0.51 | -0.76 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 4.64 | 7.5 | 8.42 | 5.83 | 6.05 | |||||
Total Debt / Total Capital | 4.43 | 6.97 | 7.76 | 5.51 | 5.71 | |||||
LT Debt/Equity | 2.31 | 7.5 | 5.6 | 5.83 | 6.05 | |||||
Long-Term Debt / Total Capital | 2.21 | 6.97 | 5.16 | 5.51 | 5.71 | |||||
Total Liabilities / Total Assets | 4.88 | 7.06 | 7.87 | 5.68 | 5.87 | |||||
EBIT / Interest Expense | 306.93 | -27.72 | -54.24 | 0.31 | 14.95 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 307.57 | -109.6 | 92.79 | -102.1 | 648.56 | |||||
Gross Profit, 1 Yr. Growth % | 307.57 | -109.6 | 92.79 | -102.1 | 648.56 | |||||
EBITA, 1 Yr. Growth % | 309.84 | -109.93 | 90.76 | -100.36 | 3.71K | |||||
EBIT, 1 Yr. Growth % | 309.84 | -109.93 | 90.76 | -100.36 | 3.71K | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 313.95 | -110.32 | 87.51 | -99.26 | -1.81K | |||||
Net Income, 1 Yr. Growth % | 313.95 | -110.32 | 87.51 | -99.26 | -1.81K | |||||
Normalized Net Income, 1 Yr. Growth % | 313.95 | -110.32 | 87.51 | -99.26 | -1.81K | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 313.95 | -110.32 | 87.51 | -99.26 | -1.84K | |||||
Accounts Receivable, 1 Yr. Growth % | -37.04 | 17.65 | -20 | 275 | -38.33 | |||||
Total Assets, 1 Yr. Growth % | 45.72 | -5.5 | -9.98 | -6.11 | -3.24 | |||||
Tangible Book Value, 1 Yr. Growth % | 48.5 | -7.67 | -10.76 | -3.88 | -3.43 | |||||
Common Equity, 1 Yr. Growth % | 48.5 | -7.67 | -10.76 | -3.88 | -3.43 | |||||
Cash From Operations, 1 Yr. Growth % | -22.41 | 216.09 | -87.37 | 32.38 | 38.48 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 322.38 | -111.96 | 59.22 | -100.4 | 3.05K | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 318.14 | -111.57 | 61.1 | -101.59 | 758.78 | |||||
Dividend Per Share, 1 Yr. Growth % | 23.38 | 2.11 | -22.68 | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 88.87 | -37.46 | -56.98 | -79.9 | -60.39 | |||||
Gross Profit, 2 Yr. CAGR % | 88.87 | -37.46 | -56.98 | -79.9 | -60.39 | |||||
EBITA, 2 Yr. CAGR % | 89.4 | -36.22 | -56.49 | -91.69 | -62.86 | |||||
EBIT, 2 Yr. CAGR % | 89.4 | -36.22 | -56.49 | -91.69 | -62.86 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 90.19 | -34.65 | -56.01 | -88.22 | -64.4 | |||||
Net Income, 2 Yr. CAGR % | 90.19 | -34.65 | -56.01 | -88.22 | -64.4 | |||||
Normalized Net Income, 2 Yr. CAGR % | 90.19 | -34.65 | -56.01 | -88.22 | -64.4 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 90.19 | -34.65 | -56.01 | -88.2 | -64.01 | |||||
Accounts Receivable, 2 Yr. CAGR % | -19.14 | -13.93 | -2.99 | 73.21 | 52.07 | |||||
Total Assets, 2 Yr. CAGR % | 26.11 | 17.35 | -7.77 | -8.07 | -4.68 | |||||
Tangible Book Value, 2 Yr. CAGR % | 27.75 | 17.1 | -9.23 | -7.39 | -3.66 | |||||
Common Equity, 2 Yr. CAGR % | 27.75 | 17.1 | -9.23 | -7.39 | -3.66 | |||||
Cash From Operations, 2 Yr. CAGR % | 6.35 | 56.6 | -36.81 | -59.11 | 35.39 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 90.72 | -28.92 | -56.36 | -92.06 | -64.69 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 89.94 | -30.45 | -56.83 | -84.02 | -63.09 | |||||
Dividend Per Share, 2 Yr. CAGR % | 12.55 | 12.24 | -11.15 | -12.07 | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 85.17 | -30.04 | -8.98 | -84.29 | -32.87 | |||||
Gross Profit, 3 Yr. CAGR % | 85.17 | -30.04 | -8.98 | -84.29 | -32.87 | |||||
EBITA, 3 Yr. CAGR % | 85.79 | -29.12 | -8.1 | -91.18 | -35.92 | |||||
EBIT, 3 Yr. CAGR % | 85.79 | -29.12 | -8.1 | -91.18 | -35.92 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 86.88 | -28 | -7.13 | -88.73 | -38.06 | |||||
Net Income, 3 Yr. CAGR % | 86.88 | -28 | -7.13 | -88.73 | -38.06 | |||||
Normalized Net Income, 3 Yr. CAGR % | 86.88 | -28 | -7.13 | -88.73 | -38.06 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 87.27 | -28 | -7.13 | -88.72 | -37.6 | |||||
Accounts Receivable, 3 Yr. CAGR % | -22.84 | -8.37 | -16.01 | 52.25 | 22.76 | |||||
Total Assets, 3 Yr. CAGR % | 21.52 | 14.55 | 7.42 | -7.22 | -6.48 | |||||
Tangible Book Value, 3 Yr. CAGR % | 22.94 | 14.65 | 6.96 | -7.48 | -6.09 | |||||
Common Equity, 3 Yr. CAGR % | 22.94 | 14.65 | 6.96 | -7.48 | -6.09 | |||||
Cash From Operations, 3 Yr. CAGR % | 0.81 | 52.91 | -32.34 | -19.15 | -38.59 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 88.47 | -24.22 | -7 | -90.9 | -41.67 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 87.36 | -25.27 | -7.97 | -85.65 | -39.68 | |||||
Dividend Per Share, 3 Yr. CAGR % | 10.72 | 8.95 | -0.87 | -7.58 | -8.22 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 95.07 | -12.32 | 3.27 | -57.52 | -34.74 | |||||
Gross Profit, 5 Yr. CAGR % | 95.07 | -12.32 | 3.27 | -57.52 | -34.74 | |||||
EBITA, 5 Yr. CAGR % | 97.03 | -11.56 | 3.96 | -69.93 | -36.04 | |||||
EBIT, 5 Yr. CAGR % | 97.03 | -11.56 | 3.96 | -69.93 | -36.04 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 99.71 | -10.62 | 4.78 | -65.1 | -36.72 | |||||
Net Income, 5 Yr. CAGR % | 99.71 | -10.62 | 4.78 | -65.1 | -36.72 | |||||
Normalized Net Income, 5 Yr. CAGR % | 99.71 | -10.62 | 4.78 | -65.1 | -36.72 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 103.55 | -9.97 | 4.91 | -65.07 | -36.44 | |||||
Accounts Receivable, 5 Yr. CAGR % | -20.64 | -17.07 | -15.44 | 18.2 | 6.5 | |||||
Total Assets, 5 Yr. CAGR % | 14.75 | 12.26 | 8.83 | 4.9 | 2.41 | |||||
Tangible Book Value, 5 Yr. CAGR % | 15.76 | 12.64 | 8.89 | 5.27 | 2.58 | |||||
Common Equity, 5 Yr. CAGR % | 15.76 | 12.64 | 8.89 | 5.27 | 2.58 | |||||
Cash From Operations, 5 Yr. CAGR % | -7.56 | 42.85 | -16.37 | -9.78 | -10.7 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 37.2 | -7.85 | 4.98 | -69.27 | -36.87 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 37.59 | -8.72 | 4.16 | -59.67 | -36.15 | |||||
Dividend Per Share, 5 Yr. CAGR % | 11.55 | 10.83 | 1.39 | 0 | -0.52 |
- Stock Market
- Equities
- HBMN Stock
- Financials HBM Healthcare Investments AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















